Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 25 Lymphoid 6 Myeloid 4 Sarcoma 2 Head & Neck 1 Genitourinary 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

lutetium Lu 177 dotatate 30 Magnetic Resonance Spectroscopy 25 pembrolizumab 21 Specimen Handling 18 Nivolumab 17 cabozantinib 14 lenvatinib 12 Everolimus 12 trametinib 11 gallium Ga 68 dotatate 10 dabrafenib 10 Ipilimumab 10 Carboplatin 10 Cisplatin 8 atezolizumab 7 Temozolomide 7 Lutetium-177 7 X-Rays 6 Etoposide 6 Capecitabine 6 surufatinib 5 lanreotide 5 fluorodopa F 18 5 cemiplimab 5 Vemurafenib 5 Paclitaxel 5 Octreotide 5 Lutetium 5 Fluorodeoxyglucose F18 5 Disulfides 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Mitoxantrone × Endocrine × 1 year × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡